Market Place
Sourcing Support
Farxiga approved in the US for the treatment of paediatric type-2 diabetes
13 Jun 2024 //
PRESS RELEASE
AstraZeneca champions early kidney disease diagnosis with modelling data
11 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
AstraZeneca aims for $80 bln in total revenue by 2030
21 May 2024 //
REUTERS
AstraZeneca beats revenue, profit estimates on resilient demand
25 Apr 2024 //
REUTERS
AstraZeneca cries havoc over CKD`s hit on economies, environment
15 Apr 2024 //
FIERCE PHARMA
TheracosBio`s BRENZAVVY® Non-Inferior To Dapagliflozin
12 Apr 2024 //
BUSINESSWIRE
Zydus Pharma`s Generic Dapagliflozin Receives Approval in the U.S.
28 Feb 2024 //
FDA
Zibotentan/dapagliflozin combination showed albuminuria reduction in patients
03 Nov 2023 //
BUSINESSWIRE
Glenmark to launch Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin
18 Oct 2023 //
INDIAN PHARMA POST
Forxiga met primary endpoint in T2NOW Phase III trial
04 Oct 2023 //
PRESS RELEASE
USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients
04 Sep 2023 //
MEDICAL DIALOGUES
AZ`s Dobber talks SGTL2, GLP-1 clash in heart failure
30 Aug 2023 //
FIERCE PHARMA
At ESC, AstraZeneca shows Farxiga`s benefits across indications
28 Aug 2023 //
FIERCE PHARMA
Forxiga approved in China to reduce the risk of cardiovascular death
18 Aug 2023 //
PRESS RELEASE
AstraZeneca gets GCGI approval to import heart failure drug
25 Jul 2023 //
ECONOMIC TIMES
AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes
27 Jun 2023 //
PHARMAFILE
AstraZeneca’s dapagliflozin recommended by NICE
19 May 2023 //
PHARMATIMES
Jamp Pharma Group receives Health Canada approval for PrJAMP Dapagliflozin
17 May 2023 //
NEWSWIRE
AZ`s Farxiga scores expanded heart failure nod
10 May 2023 //
FIERCE PHARMA
Alkem`s Generic Dapagliflozin, Metformin HCL Receives Approval in the U.S.
04 May 2023 //
FDA
Viatris` Dapagliflozin Receives Approval in Europe
04 Apr 2023 //
EMA
We are happy to announce our USDMF filing of Dapagliflozin Amorphous to the USFDA.
02 Mar 2023 //
PRESS RELEASE
NPPA fixes retail price of 74 drug formulations
27 Feb 2023 //
ECONOMIC TIMES
AZ`s Forxiga scores expanded heart failure indication in EU
08 Feb 2023 //
FIERCE PHARMA
AstraZeneca to acquire CinCor Pharma in nearly $2 billion deal
10 Jan 2023 //
PRESS RELEASE
Forxiga recommended for approval in the EU by CHMP for chronic heart failure
19 Dec 2022 //
PRESS RELEASE
Dapagliflozin approved for heart failure across LVEFs
12 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
Eli Lilly, Boehringer launch `Cuide Su Corazón` Latina women
05 Dec 2022 //
FIERCEPHARMA
AstraZeneca’s Farxiga shows benefits for heart failure patients in phase 3 trial
09 Nov 2022 //
PMLIVE
Glenmark Pharma launches drug for diabetic patients with comorbidities
20 Oct 2022 //
ECONOMIC TIMES
Forxiga approved in China for the treatment of chronic kidney disease
05 Sep 2022 //
PRESS RELEASE
New Data show Farxiga lowers the risk of cardiovascular death in patients
27 Aug 2022 //
PRESS RELEASE
Jardiance poised for challenge to AZ`s Farxiga in CKD: Spherix
24 Jun 2022 //
FIERCEPHARMA
Dapagliflozin meets primary endpoint in Deliver phase-III trial
23 May 2022 //
EXPRESS PHARMA
First treatment option indicated for CKD in Scotland for 20 years
10 May 2022 //
PHARMATIMES
FARXIGA met primary endpoint in DELIVER Phase III trial
05 May 2022 //
BUSINESSWIRE
Zydus receives final approval from US FDA for Dapagliflozin tablets
23 Feb 2022 //
EXPRESS PHARMA
Timely intervention: First chronic kidney disease treatment in 20 years
03 Feb 2022 //
PHARMATIMES
NPPA fixes retail price of 20 new drugs
06 Dec 2021 //
PHARMABIZ
NICE recommend dapagliflozin for treating chronic kidney disease
08 Nov 2021 //
EUROPEANPHARMACEUTICALREVIEW
Diabetes drug dapagliflozin recommended by NICE for chronic kidney disease
08 Nov 2021 //
PHARMAFILE
NICE issues draft recommendation for new kidney disease treatment
04 Nov 2021 //
PHARMATIMES
Forxiga (dapagliflozin) - Important Safety Information from AstraZeneca
29 Oct 2021 //
FIRSTWORDPHARMA
NPPA fixes retail price of of anti-diabetic FDC of dapagliflozin & metformin HCL
30 Jun 2021 //
PHARMABIZ
Dapagliflozin Reduces Incidence of New Onset T2DM in Patients With CKD
29 Jun 2021 //
MEDICAL DIALOGUE
Sun Pharma acquires rights to trademarks of three diabetes drug in India from AZ
29 May 2021 //
ECONOMICTIMES
AZ diabetes med Farxiga scores big expansion into kidney disease
30 Apr 2021 //
FIERCE PHARMA
FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease
30 Apr 2021 //
BUSINESSWIRE
FDA Approves Treatment for Chronic Kidney Disease
30 Apr 2021 //
FDA
Forxiga accepted for use within NHS Scotland for chronic heart failure
14 Apr 2021 //
PHARMFILE
Update on the DARE-19 Phase III trial for Farxiga in COVID-19
13 Apr 2021 //
PRESS RELEASE
AZ`s Farxiga gets rough FDA review date for groundbreaking move into CKD
07 Jan 2021 //
ENDPTS
AstraZeneca`s Farxiga scores speedy FDA review in CKD
06 Jan 2021 //
FIERCEPHARMA
FARXIGA Granted Priority Review in the US for the Treatment
05 Jan 2021 //
BIOSPACE
New heart failure drug for thousands of UK patients given go ahead
31 Dec 2020 //
INDEPENDENT
MHLW Approves Label Expansions for Forxiga, Trelegy, Evrenzo, Cabometyx and More
30 Nov 2020 //
PHARMA JAPAN
AstraZeneca’s Forxiga approved in EU to treat chronic heart failure
06 Nov 2020 //
EUROPEANPAHRAMCEUTICALREVIEW
Zydus Cadila gets tentative US FDA approval for Dapagliflozin Tablets
30 Oct 2020 //
EXPRESSPHARMA
